JP2013511966A5 - - Google Patents

Download PDF

Info

Publication number
JP2013511966A5
JP2013511966A5 JP2012540419A JP2012540419A JP2013511966A5 JP 2013511966 A5 JP2013511966 A5 JP 2013511966A5 JP 2012540419 A JP2012540419 A JP 2012540419A JP 2012540419 A JP2012540419 A JP 2012540419A JP 2013511966 A5 JP2013511966 A5 JP 2013511966A5
Authority
JP
Japan
Prior art keywords
fusion polypeptide
seq
amino acid
domain
polypeptide according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012540419A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013511966A (ja
Filing date
Publication date
Priority claimed from DE102009047243A external-priority patent/DE102009047243A1/de
Application filed filed Critical
Publication of JP2013511966A publication Critical patent/JP2013511966A/ja
Publication of JP2013511966A5 publication Critical patent/JP2013511966A5/ja
Pending legal-status Critical Current

Links

JP2012540419A 2009-11-27 2010-11-24 単一特異性ポリペプチド試薬 Pending JP2013511966A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102009047243A DE102009047243A1 (de) 2009-11-27 2009-11-27 Monospezifische Polypeptidreagenzien
DE102009047243.6 2009-11-27
PCT/EP2010/068134 WO2011064257A2 (de) 2009-11-27 2010-11-24 Monospezifische polypeptidreagenzien

Publications (2)

Publication Number Publication Date
JP2013511966A JP2013511966A (ja) 2013-04-11
JP2013511966A5 true JP2013511966A5 (enExample) 2014-01-09

Family

ID=43589669

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012540419A Pending JP2013511966A (ja) 2009-11-27 2010-11-24 単一特異性ポリペプチド試薬

Country Status (8)

Country Link
US (2) US9163079B2 (enExample)
EP (1) EP2504359B1 (enExample)
JP (1) JP2013511966A (enExample)
AU (1) AU2010323144B2 (enExample)
CA (1) CA2782016C (enExample)
DE (1) DE102009047243A1 (enExample)
DK (1) DK2504359T3 (enExample)
WO (1) WO2011064257A2 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7919092B2 (en) 2006-06-13 2011-04-05 Oncomed Pharmaceuticals, Inc. Antibodies to notch receptors
WO2008091641A2 (en) 2007-01-24 2008-07-31 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
CN102112490B (zh) 2008-07-08 2014-10-22 昂考梅德药品有限公司 Notch1受体结合剂和其使用方法
DE102009047243A1 (de) * 2009-11-27 2011-06-01 Orgentec Diagnostika Gmbh Monospezifische Polypeptidreagenzien
WO2013156054A1 (en) * 2012-04-16 2013-10-24 Universität Stuttgart The igm and ige heavy chain domain 2 as covalently linked homodimerization modules for the generation of fusion proteins with dual specificity
WO2015153997A2 (en) * 2014-04-04 2015-10-08 Oncomed Pharmaceuticals, Inc. Notch3 antibodies and uses thereof
HUE065861T2 (hu) * 2016-08-26 2024-06-28 Sanofi Sa Szelektív könnyûlánc-párosítást elõsegítõ multispecifikus antitestek
AU2017350947B2 (en) * 2016-10-28 2024-02-15 Washington University Anti-ApoE antibodies
CN113518823B (zh) * 2019-01-07 2025-05-02 托马斯杰斐逊大学 多功能的融合蛋白及其用途
ES3031566T3 (en) 2019-06-24 2025-07-09 Univ Stuttgart Tnfr2 agonists with improved stability

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2126967A1 (en) 1992-11-04 1994-05-11 Anna M. Wu Novel antibody construct
US6015662A (en) 1996-01-23 2000-01-18 Abbott Laboratories Reagents for use as calibrators and controls
DE69726003T2 (de) * 1996-07-16 2004-08-26 Andreas Plückthun Immunglobulin-superfamilie domainen und fragmente mit erhöhter löslichkeit
JP3614866B2 (ja) 1997-06-12 2005-01-26 リサーチ コーポレイション テクノロジーズ，インコーポレイティド 人工抗体ポリペプチド
US6151296A (en) 1997-06-19 2000-11-21 Qualcomm Incorporated Bit interleaving for orthogonal frequency division multiplexing in the transmission of digital signals
EP1190061A1 (en) 1999-06-07 2002-03-27 Neorx Corporation Streptavidin expressed gene fusions and methods of use thereof
DE10001372A1 (de) 2000-01-14 2001-08-02 Deutsches Krebsforsch Anti-CD3-Einzelketten-Antikörper mit humanem Cmu3- und Cmu4- Domänen
US7829084B2 (en) * 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
AU2003210060B2 (en) 2002-03-22 2010-02-25 Aprogen, Inc. Humanized antibody and process for preparing same
US8034902B2 (en) * 2005-05-04 2011-10-11 Quark Pharmaceuticals, Inc. Recombinant antibodies against CD55 and CD59 and uses thereof
ES2335232T3 (es) * 2005-06-21 2010-03-23 Xoma Technology Ltd. Anticuerpos y fragmentos de los mismos que se unen a la il-1 beta.
EP1757622B1 (en) * 2005-08-26 2009-12-23 PLS Design GmbH Bivalent IgY antibody constructs for diagnostic and therapeutic applications
EP1962961B1 (en) * 2005-11-29 2013-01-09 The University Of Sydney Demibodies: dimerisation-activated therapeutic agents
US8273030B2 (en) 2005-12-01 2012-09-25 Atcor Medical Pty Ltd Method of estimating pulse wave velocity
ATE509033T1 (de) 2006-03-20 2011-05-15 Univ California Manipulierte anti-prostatastammzellenantigen (psca)-antikörper für krebs-targeting
GB0614780D0 (en) * 2006-07-25 2006-09-06 Ucb Sa Biological products
CA2682605A1 (en) * 2007-04-18 2008-10-30 Zymogenetics, Inc. Single chain fc, methods of making and methods of treatment
US20080283653A1 (en) * 2007-04-20 2008-11-20 Invista North America Sarl Compact continuous over end take-off (oeto) creel with tension control
CA2689895A1 (en) * 2007-05-31 2008-12-04 Genmab A/S Non-glycosylated recombinant monovalent antibodies
EP2116555A1 (en) * 2008-05-08 2009-11-11 Bayer Schering Pharma Aktiengesellschaft Use of a radioactively labelled molecule specifically binding to ED-B fibronectin in a method of treatment of Hodgkin lymphoma
DE102009047243A1 (de) * 2009-11-27 2011-06-01 Orgentec Diagnostika Gmbh Monospezifische Polypeptidreagenzien

Similar Documents

Publication Publication Date Title
ES2637667T3 (es) Un anticuerpo que se une específicamente al factor de crecimiento insulinoide 1
ES3013602T3 (en) Antigen binding molecules and methods of use thereof
ES2643640T3 (es) Agentes para tratamiento de enfermedad
EP3670534A3 (en) Human fgf receptor and beta-klotho binding proteins
HRP20201191T1 (hr) Mutirani multispecifični fab fragmenti antitijela
KR20160014010A (ko) 신규 항체
BRPI0607315A2 (pt) polinucleotìdeo isolado, vetor de expressão, composição, método de produzir uma molécula de ligação de antìgeno, molécula de ligação de antìgeno e o uso da mesma-, método para detectar in vivo ou in vitro a presença de egfr em uma amostra, célula hospedeira engendrada, composição farmacêutica e o uso da mesma
CN109661235B (zh) 抗原结合分子及其使用的方法
AR077088A1 (es) Proteinas biespecificas de union a antigeno
Macpherson et al. Isolation of antigen-specific, disulphide-rich knob domain peptides from bovine antibodies
EA201490262A1 (ru) Модифицированные белки и пептиды
DK2504359T3 (da) Monospecifikke polypeptidreagenser
RU2018141360A (ru) Contorsbody - одноцепочечный связывающий мишень агент
RU2012143798A (ru) Биспецифические антитела
RU2014102007A (ru) Методы предсказания, обнаружения и уменьшения неспецифической интерференции белков в способах анализа с использованием одиночных вариабельных доменов иммуноглобулинов
RU2015152077A (ru) Тримерные антигенсвязывающие молекулы
Tigue et al. MEDI1873, a potent, stabilized hexameric agonist of human GITR with regulatory T-cell targeting potential
Nilvebrant et al. Selection and in vitro characterization of human CD44v6‐binding antibody fragments
JP7084057B2 (ja) 新規抗ｐａｄ２抗体
ATE535546T1 (de) Humane monoklonale antikörper, die spezifisch an ifg-ii binden
Miura et al. Nucleotide-dependent behavior of single molecules of cytoplasmic dynein on microtubules in vitro
EP3036259B1 (en) Antibodies specifically binding to her3
TWI593967B (zh) 二級抗體所辨識之抗原決定位及其用途
RU2020112751A (ru) Отличные от человека животные, у которых экспрессируется гуманизированный комплекс c1q
CN102863529A (zh) 一种vegf单抗及包含该单抗的骨折愈合评价抗体芯片